The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.

Trial Details

NCT ID

NCT06851299

Phase

PHASE2

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• trop2-ADC
• ADC +anti-angiogenic drug
• ADC + PD1 monoclonal antibody +anti-angiogenic drug

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• 1\) adult female patients (aged 18-70 years) with metastatic triple negative breast cancer confirmed by pathology or imaging;
• 2\) no more than two previous lines of therapy for metastatic disease;
• 3\) ECOG performance status ≤2 and expected survival time ≥ 3 months;
• 4\) At least one measurable lesion on imaging within 2 weeks before enrollment; Or simple bone metastases;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.